Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company's system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company's focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:DCTHD
CUSIPN/A
Phone212-489-2100
Debt
Debt-to-Equity RatioN/A
Current Ratio0.43
Quick Ratio0.32
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.71 million
Price / Sales1.03
Cash FlowN/A
Price / CashN/A
Book Value($6.91) per share
Price / Book-0.45
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-45,110,000.00
Net Margins-993.88%
Return on EquityN/A
Return on Assets-275.35%
Miscellaneous
Employees46
Outstanding Shares900,000
Delcath Systems (OTCMKTS:DCTHD) Frequently Asked Questions
What is Delcath Systems' stock symbol?
Delcath Systems trades on the OTCMKTS under the ticker symbol "DCTHD."
When did Delcath Systems' stock split? How did Delcath Systems' stock split work?
Shares of Delcath Systems reverse split on Monday, November 6th 2017. The 1-350 reverse split was announced on Friday, November 3rd 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, November 3rd 2017. An investor that had 100 shares of Delcath Systems stock prior to the reverse split would have 0 shares after the split.
How were Delcath Systems' earnings last quarter?
Delcath Systems, Inc. (OTCMKTS:DCTHD) posted its quarterly earnings results on Friday, November, 11th. The medical device company reported ($231.00) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1,151.50) by $920.50. The medical device company had revenue of $0.44 million for the quarter. During the same quarter in the previous year, the business posted ($686.00) EPS. View Delcath Systems' Earnings History.
Who are some of Delcath Systems' key competitors?
Some companies that are related to Delcath Systems include Cytori Therapeutics (CYTX), Alliqua Biomedical (ALQA), United American Healthcare (UAHC), Regenicin (RGIN), Avinger (AVGR), Viatar CTC Solutions (VRTT), Invivo Therapeutics (NVIV), Atossa Genetics (ATOS), Cytocore common stock (MDIT), Amedica (AMDA), Calmare Therapeutics (CTTC), OxySure Therapeutics (OXYS), Encision, Inc. Common Stock (ECIA), TearLab (TEAR) and AdvanSource Biomaterials Corpration Common Stock (ASNB).
Who are Delcath Systems' key executives?
Delcath Systems' management team includes the folowing people:
- Roger G. Stoll Ph.D., Chairman of the Board (Age 74)
- Jennifer K. Simpson Ph.D., President, Chief Executive Officer, Director (Age 48)
- Barbra C. Keck, Chief Financial Officer, Secretary (Age 39)
- John Purpura, Executive Vice President - Global Head of Operations (Age 55)
- Simon C. Pedder Ph.D., Director (Age 56)
- William Dodge Rueckert, Independent Director (Age 64)
- Marco Taglietti M.D., Independent Director (Age 57)
Has Delcath Systems been receiving favorable news coverage?
News articles about DCTHD stock have been trending somewhat negative recently, according to Accern Sentiment Analysis. The research group rates the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Delcath Systems earned a news sentiment score of -0.06 on Accern's scale. They also assigned media stories about the medical device company an impact score of 44.13 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
How do I buy shares of Delcath Systems?
Shares of DCTHD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Delcath Systems' stock price today?
One share of DCTHD stock can currently be purchased for approximately $3.11.
How big of a company is Delcath Systems?
Delcath Systems has a market capitalization of $2.69 million and generates $2.71 million in revenue each year. Delcath Systems employs 46 workers across the globe.
How can I contact Delcath Systems?
Delcath Systems' mailing address is 1633 BROADWAY SUITE 22C, NEW YORK NY, 10019. The medical device company can be reached via phone at 212-489-2100 or via email at [email protected]
MarketBeat Community Rating for Delcath Systems (DCTHD)
MarketBeat's community ratings are surveys of what our community members think about Delcath Systems and other stocks. Vote "Outperform" if you believe DCTHD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DCTHD will underperform the S&P 500 over the long term. You may vote once every thirty days.
